WARMINSTER, Pa., Oct. 23, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ABUS), (“Arbutus” or the “Company”) a clinical-stage ...

导读显性乙型肝炎病毒即慢性乙型肝炎病毒（Chronic Hepatitis B,CHB）感染的特征是血清中检测到乙肝表面抗原（hepatitis B surface antigen, ...

Regular Abstracts Accepted as Poster Presentations Presentation Title: Soluble Immune Biomarker Profiling of Chronic Hepatitis B Subjects Treated with Imdusiran in Combination with Pegylated ...

Vir Biotechnology, Inc. (NASDAQ:VIR) today announced it will present new data from the Phase 2 SOLSTICE clinical trial ...

Indigenous communities and organizations, and companies operating in Indigenous communities, should first try to obtain rapid tests from provinces and territories or through their local Indigenous ...

单独分析HBcAb意义不大，可与其他HBV血清标志物相互补充分析，也就是我们常说的乙肝“两对半”。如HBsAg、HBeAg和HBcAb同时呈阳性，表示乙肝 大三阳 ；HBsAg、HBeAb和HBcAb同时呈阳性，表示乙肝小三阳。

WARMINSTER, Pa., Oct. 01, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage ...

POC HBV testing was associated with faster turnaround time for results and higher rates of treatment initiation when compared with standard laboratory-based assays.

Unlike chimeric antigen receptor (CAR) T-cell therapies, which can identify surface antigens, TCR-T cell therapies like ...

The global hepatitis B diagnostic tests market is on the brink of significant expansion, driven by a surge in disease incidence, heightened awareness campaigns, and rapid advancements in diagnostic ...

Hepatitis B virus (HBV) infection is an important health problem and a major cause of chronic hepatitis that can lead to cirrhosis and hepatocellular carcinoma. Durable viral suppression has been ...

Enara Bio has snagged $32.5 mil­lion in a Se­ries B fundraise, backed in part by Pfiz­er’s ven­ture arm, to help de­vel­op a pre­clin­i­cal pipeline of … ...